Adjunct Intravitreous Triamcinolone Acetonide in the Treatment of Diabetic Macular Edema with Anti-VEGF Agents

Table 2

Main outcome results.

	Group 1	Group 2	value
Mean 1-year BCVA, logMAR	0.41 (20/51)	0.61 (20/81)	0.003
Mean final BCVA, logMAR	0.39 (20/49)	0.63 (20/84)	0.0005
Average change in BCVA at 1 year	+2.5 letters	−2.5 letters	0.32
Average change in BCVA final	+3.5 letters	−3.5 letters	0.048
Mean CSMT at 1 year	332 μm	381 μm	0.039
Mean final CSMT	330 μm	360 μm	0.29
Average change in CSMT at 1 year	−92 μm	−46 μm	0.049
Average change in CSMT	−94 μm	−68 μm	0.26